MacroGenics Goes Public, Becomes 30th Biotech IPO in 2013
October 15, 2013
MacroGenics, which went public Thursday and closed the day up 49.5% ($24.99) from its IPO price of $16, became the 30th U.S.-based, VC-backed pharmaceuticals & biotechnology company to go public in 2013, the most on record. The Rockville, MD-based cancer-treatment company raised $80 million in its IPO on the NASDAQ. MacroGenics investors include Alta Partners, Vivo Ventures, Clarus Ventures, InterWest Partners, TPG Biotech and numerous other firms, companies and individuals.